Modulation of Oncogenes with Preactivated Compounds

  • Kirpal S. Gulliya
Part of the Medical Intelligence Unit book series (MIU.LANDES)


In previous chapters we have described the antitumor and antiviral properties of novel compounds discovered via the application of the process of preactivation. The studies of the mechanism of action of these compounds have also been summarized. In this concluding chapter, data from ongoing studies related to the effect of preactivated merocyanine 540 (pMC540) on the modulation of selected oncogenes will be discussed.


L1210 Cell L1210 Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sager R. Tumor suppressor genes: The puzzle and the promise. Science 1989; 246: 1406–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Watt R, Wang A, Schein P. Altered c-myc gene expression in Burkitt lymphoma cells following nitrogen mustard treatment. Proc Am Assoc Cancer Res 1986; 27: 232.Google Scholar
  3. 3.
    Venturelli D, Lange B, Narni F et al. Prognostic significance of short term effect of chemotherapy on MYC and histone H3 m RNA levels in acute leukemia patients. Proc Natl Acad Sci USA 1988; 85: 3590–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Greenberg M, Ziff E. Stimulation of 3T3 cells induces transcriptions of the c-fos proto-oncogene. Nature 1984; 311: 433–38.PubMedCrossRefGoogle Scholar
  5. 5.
    Kovacs E, Oppenheim J, and Young H. Induction of c fos and c-myc expression in T-lymphocytes after treatment with recombinant interferon alpha. J Immunol 1986; 137: 3649–51.PubMedGoogle Scholar
  6. 6.
    Kruiger W, Cooper J, Hunter T et al. Platelet-derived growth factor induces rapid but transient expression of the c-fos oncogene and protein. Nature 1984; 312: 711–16.CrossRefGoogle Scholar
  7. 7.
    Greenberg M, Ziff E, Greene L. Stimulation of neronal acetylcholine receptors induces rapid gene transcription. Science 1986; 234: 80–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Morgan J, Cohen D, Hempstead J et al. Mapping patterns of c fos expression in the central nervous system after seizure. Science 1987; 237: 192–97.PubMedCrossRefGoogle Scholar
  9. 9.
    Siebenblast U, Bressler P, Kelly K. Two distinct mechanisms of transcriptional control operate on c-myc during differentiation of HL-60 cells. Mol Cell Biol 1988; 8: 867–74.Google Scholar
  10. 10.
    Trepel J, Colamonici O, Kelly K et al. Transcriptional inactivation of c-myc and the transferrin receptor in dibutyril cyclic-AMP-treated HL-60 cells. Mol Cell Biol 1987; 7: 2644–48.PubMedGoogle Scholar
  11. 11.
    Reitsma P, Rothberg P, Astrin S et al. Rgulation of c-myc expression in HL-60 leukemic cells by a vitamin D metabolite. Nature 1983; 322: 848–50.Google Scholar
  12. 12.
    Salomon DS, Perrotean J. Growth factors in cancer and their relationship to oncogenes. Cancer Invest 1986; 4: 43–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Battey J, Moulding C, Taub R., Murphy W, Stewart T, Potter H, Lenoir G, Leder P. The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell 1983; 34: 779–87.PubMedCrossRefGoogle Scholar
  14. 14.
    Capon D, Chen E, Levinson A., Seeburg P, Goeddel D. Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature (Lond.) 1983; 302: 33–37.CrossRefGoogle Scholar
  15. 15.
    Dalla Favera R, Wong-Staal, F, Gallo, R. Oncogene amplification in promyelocytic leukemia cell line HL-60 and primary leukemic cells of the same patient. Nature (Lond.) 1982; 299: 61–63.CrossRefGoogle Scholar
  16. 16.
    Schwab M, Ellison J, Busch M, Rosenau W, Varmus H, Bishop J. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984; 81: 4940–44.PubMedCrossRefGoogle Scholar
  17. 17.
    Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (Wash. DC) 1984; 224: 1121–24.CrossRefGoogle Scholar
  18. 18.
    Watt R, Wang A, Schein P. Altered c-myc gene expression in Burkitt lymphoma cells following nitrogen mustard treatment. Proc Am Assoc Cancer Res 1986; 27: 232.Google Scholar
  19. 19.
    Venturelli, D, Lange B, Narni F, Selleri L, Torelli U, Calabreta B. Prognostic significance of “short term” effects of chemotherapy on MYC and histone H3 mRNA levels in acute leukemia patients. Proc Natl Acad Sci USA, 1988; 85: 3590–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Gulliya KS, Pervaiz S, Dowben RM, Matthews, JL. Tumor cell specific dark cytotoxicity of light-exposed merocyanine 540: implications for systemic therapy without light. Photochem Photobiol 1990; 51: 831–38.CrossRefGoogle Scholar
  21. 21.
    Chanh TC, Allan JS, Pervaiz S, Matthews JL, Gulliya KS. Preactivated merocyanine 540 inactivates HIV-1 and SIV: potential therapeutic and blood banking applications. J AIDS 1992; 5: 188–95.Google Scholar
  22. 22.
    Wiggs, R. B., Lobprise, H.B., Matthews, J.L. and Gulliya, K.S. Effects of preactivated MC540 in the treatment of lymphocytic plasmacytic stomatitis in feline leukemia virus and feline immunodeficiecy virus positive cats. J. Veterinary Dentistry, 1993; 10: 9–13.Google Scholar
  23. 23.
    Gulliya, K. S., Sharma, R. K., Matthews, J. L., Benniston, A. C., Harriman, A., and Nemunaitis, J. In vitro and in vivo growth suppression of MCF-7 human breast cancer by novel photoproducts and tamoxifen. Cancer 1994; 74: 1725–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Sharma RK Gulliya KS. Growth inhibitory effects of pMC540 and merodantoin on established MCF-7 human breast tumor xenografts. In Vivo 1995; 9: 103–108.Google Scholar
  25. 25.
    Lowry OH, Rosebrough N J, Farr AL, Randall RJ. Protein measurement with the folin ohenol reagent. J Biol Chem, 1951; 193: 265–75.PubMedGoogle Scholar
  26. 26.
    Laemmle UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5.CrossRefGoogle Scholar
  27. 27.
    Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350–54.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaufmann S, Coffey D, Shaper J. Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Exp Cell Res 1981; 132: 105–23.PubMedCrossRefGoogle Scholar
  29. 29.
    Persson H, Leder P. Nuclear localization and DNA binding properties of a protein expressed by human c-myc oncogene. Science, 1984; 225: 718–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Futsher BW, Erickson LC. Changes in c-myc and c-fos expression in a human tumor cell line following exposure to bifunctional alkylating agents. Cancer Res 1990; 50: 62–66.Google Scholar
  31. 31.
    Gulliya KS, Frank B, Schneider U et al. Topoisomerase II-dependent novel antitumor compounds merocil and merodantoin induce apoptosis in Daudi cells. Anticancer Drugs 1994; 5: 557–66.PubMedCrossRefGoogle Scholar
  32. 32.
    Sharma RK, Arnold L, Gulliya KS. Correlation between DNA Topoisomerase II activity and cytotoxicity in pMC540 and merodantoin sensitive and resistant tumor breast cancer cells. Anticancer Research 1995; 15: 295–304.PubMedGoogle Scholar
  33. 33.
    Osheroff N, Robinson MJ, Zechiedrich EL. Mechanism of the topoisimerase II-mediated DNA cleavage-religation reaction: Inhibition of DNA religation by antineoplastic drugs. In: Potmesil M Kohn KW, eds. DNA Topoisomerases in Cancer. Oxford University Press, 1991: 230–39.Google Scholar
  34. 34.
    Rowe T, Kuffer G, Ross W. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 1985; 34: 2483–87.PubMedCrossRefGoogle Scholar
  35. 35.
    Riou JF, Multon E, Vilaren M-J et al. In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene. Biochem Biophys Res Commun 1986; 137: 157–60.CrossRefGoogle Scholar
  36. 36.
    Riou JF, Vilarem MJ, Larsen CJ et al. In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites of c-myc proto-oncogene. Natl Cancer Inst Monogr 1987; 4: 41–47.Google Scholar
  37. 37.
    Dyson PJ, Rabbitts TH. Chromatin structure around the c-myc gene in Burkitt lymphomas with upstream and downstream translocation points. Proc Natl Acad Sci USA 1985; 82: 1984–88.PubMedCrossRefGoogle Scholar
  38. 38.
    Studzinski GP, Brelvi ZS, Feldman SC et al. Participation of cmyc protein in DNA synthesis of human cells. Science 1986; 234: 467–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Iguchi-Ariga SMM, Itani T, Kiji Y et al. Possible function of the c-myc product: promotion of cellular DNA replication. EMBO J 1987; 6: 2365–71.PubMedGoogle Scholar
  40. 40.
    Little CD, Nau MM, Carney DN et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983; 306: 194–96.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Kirpal S. Gulliya
    • 1
    • 2
    • 3
  1. 1.Baylor Research InstituteBaylor University Medical CenterDallasUSA
  2. 2.Institute of Biomedical StudiesBaylor UniversityWacoUSA
  3. 3.Department of Biological ScienceUniversity of North TexasDentonUSA

Personalised recommendations